Generated by Meeveem AI
"Advancing cancer diagnostics through circulating tumour cell intelligence"
CelLBxHealth specialises in circulating tumour cell intelligence for cancer research and diagnostics. The Parsortix platform uses patented microfluidics to capture intact CTCs from whole blood, enabling downstream analysis. This minimally invasive approach provides researchers and pharmaceutical companies with repeatable access to cancer biomarkers without tissue biopsies. The platform serves biopharmaceutical companies, translational researchers and clinical laboratories worldwide. CelLBxHealth combines product solutions with GCP compliant laboratory services. This dual approach accelerates drug development, supports personalised medicine and advances patient care through accessible, repeatable cancer diagnostics.
120
Team Members
1994
Founded
Diagnostics
Sector
Hybrid
Work Environment
A world where cancer care is guided by precise, accessible biomarker intelligence, enabling every patient to receive personalised treatment based on real time tumour insights rather than invasive procedures.
Our mission is to advance the development of new cancer therapies and personalised medicine.